Meeting subject-matter, enablement andwritten-description requirements when claims reach beyond the sequences you made

1. Introduction

Engineered proteins include therapeutic antibodies and enzymes, industrial biocatalysts, diagnostic reagents, biosensors andresearch tools. They are made by three broad families of methods: rational or structure-guided design, directed evolution (iterative mutation and selection, recognised by the 2018 Nobel Prize in Chemistry awarded in part to Frances Arnold) andcomputational or AI-driven design, which was recognised in the 2024 Nobel Prize in Chemistry awarded in part to David Baker and to Demis Hassabis and John Jumper for protein structure prediction.

From a patent perspective, these approaches share a common tension. Inventors typically make and test a small number of sequences, but want claims covering a much larger family of functional variants. U.S. law requires that the specification show the inventor possessed what is claimed and teach the skilled person how to make and use the full scope of it. This article explains how to disclose designed and evolved sequences so that claims are both valuable and defensible.

2. Patent-Eligible Subject Matter (35 U.S.C. § 101)

Natural products and laws of nature are not patent-eligible. In Association for Molecular Pathology v. Myriad Genetics (2013), the Supreme Court held that isolated naturally occurring DNA is not eligible, but that complementary DNA (cDNA), which is not naturally occurring, is. The same logic shapes protein claims.

Drafting tip: describe how the claimed protein differs from the closest natural sequence in structure and function andgive measured data showing the difference. This builds the “markedly different” record early.

3. Written Description and Enablement (35 U.S.C. § 112(a))

Section 112(a) requires a written description of the invention anda disclosure that enables the skilled person to make and use it. These are separate requirements andboth are often litigated against biotechnology claims.

Written description

The specification must show that the inventor had possession of the claimed invention as of the filing date. For genus claims, courts look for a representative number of species or common structural features that distinguish members of the genus. In Ariad v. Eli Lilly (Fed. Cir. 2010, en banc) the court confirmed that written description is a separate requirement from enablement andlater decisions such as Juno Therapeutics v. Kite Pharma (Fed. Cir. 2021) held that claims defined by function alone, without adequate description of the structures that perform it, can fail.

Enablement and Amgen v. Sanofi

In Amgen Inc. v. Sanofi (2023), the Supreme Court unanimously held that claims to a genus of antibodies defined by their binding and blocking function were not enabled. Disclosing 26 antibody sequences and a roadmap for finding others, in the form of conservative substitution and a “swapping” method, was not enough to enable the full scope of a claim covering potentially millions of candidates. The Court said that the more one claims, the more one must enable.

Directed-evolution and machine-learning inventions are directly affected. A specification that says “mutate, screen andrepeat” is effectively a research plan andit risks being characterised as requiring the skilled person to repeat the inventor’s whole discovery process.

How to respond in drafting

4. What to Disclose: Designed and Evolved Sequences

A specification for an engineered protein should be built around the sequence data, but sequences alone are rarely sufficient. The table sets out the core content.

ElementWhat to includeWhy it matters
Reference (parent) sequenceSource organism, database accession, full sequence andany prior-art engineered variantsDefines the baseline against which novelty and improvement are measured
Variant sequencesFull-length sequences with SEQ ID numbers, mutation lists in a consistent numbering scheme (such as T45A) andidentity to the parentSupports each claimed species and the genus
Design or evolution methodRational design logic, library construction (error-prone PCR, shuffling, site-saturation), selection conditions, number of rounds, and, for AI methods, model type, inputs andtraining dataShows how the variants were obtained and supports reproducibility
Functional dataActivity, specificity, stability, expression levels, binding constants andassay conditions, with comparison to the parent and to benchmarksShows the technical effect and supports utility and non-obviousness
Structure and mechanismCrystal or cryo-EM structures, homology models, active-site or interface residues andrationale for the mutationsEstablishes structural features common to the genus
Negative and neutral resultsVariants that were inactive or lost function andpositions tolerant or intolerant of changeHelps define the boundaries of the genus and supports enablement
Production and useExpression systems, purification, formulation andapplicationsSatisfies the “make and use” requirement
Biological material depositsCell lines or vectors deposited where sequences alone are not sufficient to reproduce the materialProvides access to material under Budapest Treaty procedures

Sequence listings

Nucleotide and amino acid sequences disclosed in an application must be submitted in a sequence listing in the format required by the USPTO. Since July 1, 2022, applicants must use WIPO Standard ST.26, an XML-based format, in place of the earlier ST.25 text format. Sequences must be assigned sequence identifiers andthe listing is filed as a separate file that is not counted toward page limits. Practical points:

5. Claim Strategies for Engineered Proteins

No single claim format works for every case. A balanced set covers a range from narrow and certain to broad and uncertain.

Claim typeExample approachStrengths and risks
Specific sequenceAn isolated polypeptide comprising SEQ ID NO: 2Strong support and easy to prove; easy to design around
Sequence identityA polypeptide at least 90% identical to SEQ ID NO: 2 and having a specified residue at position 45Covers variants; must be supported by data across the identity range; vulnerable if the range is too wide
Defined mutation setA variant of a parent protein comprising substitutions at positions X, Y andZ, selected from specified residuesConcrete and often better supported than function-only claims
Structural motif or domainA polypeptide comprising a defined binding loop or conserved motifUseful for families; support depends on showing the motif’s role
Functional genusAny protein that binds target X with affinity better than YMost exposed after Amgen and Juno; typically hard to sustain without extensive support
Method of making or useMethod of producing the variant, or treating a condition with itComplementary andcan survive when composition claims are challenged
Related moleculesNucleic acids encoding the variant, vectors, host cells, compositions, kitsBroadens protection across the product chain

Cautions on identity and conservative-substitution language

6. Special Issues for AI-Assisted and Computational Design

7. Prior-Art Searching for Protein Inventions

Sequence-based prior art is found in both patent and non-patent sources. A thorough search should include:

Run searches before drafting to shape claim scope andagain before filing and during prosecution, since new publications continue to appear.

8. Drafting and Filing Checklist

 Item
☐Describe the closest natural sequence and show how the engineered molecule is markedly different.
☐Provide a representative set of full sequences with SEQ ID numbers across the claimed range.
☐Include assay methods, conditions andcomparative data for each key variant.
☐Identify essential residues and tolerant positions, with supporting structure–function data.
☐Describe the design, evolution, or AI workflow in enough detail to be reproducible.
☐Define identity, alignment method, conservative substitution andnumbering conventions.
☐Draft claim tiers from specific sequences to broader genera, plus method and related-molecule claims.
☐Prepare the ST.26 sequence listing and verify it against the text and claims.
☐Consider deposits of biological material where necessary.
☐Confirm inventorship and document human contribution, especially for AI-assisted work.
☐Plan foreign filings, noting differences in the treatment of functional claims and sequence-based claims.

9. Conclusion

Engineered proteins can be strongly protected, but the era of broad functional genus claims supported by a handful of examples is over. The strongest applications combine many working species, structural insight andtransparent description of the design or evolution process with claims that scale from precise sequences to carefully justified families. For AI-assisted work, the same principles apply, with added attention to inventorship and to documenting experimental validation. Planning the disclosure alongside the claims, rather than after them, is the surest way to keep that protection intact through prosecution and litigation.

This article is provided for general informational purposes and is not legal advice. Statutes, rules, fee schedules andUSPTO practice change; confirm current requirements and consult a registered patent practitioner or trademark attorney before relying on any point here.

Leave a Reply

Your email address will not be published. Required fields are marked *